Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Oakmark Global Select Fund 2023 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Oakmark Global Select Fund)

Primary Source Intelligence • Q2 2023 Letter Analysis

Oakmark Global Select Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Oakmark Global Select Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+5.7%

Annualized+7.73%

Positioning StanceConstructive

GeographyUS, Global

Digest Analysis

Quick Take

"Oakmark Global Select delivered solid Q2 performance driven by Alphabet's AI momentum and operational improvements. New positions in ConocoPhillips and Danaher capitalize on energy sector value and life sciences growth."

Executive Summary

The Oakmark Global Select Fund returned 5.7% in Q2 2023, slightly underperforming the MSCI World Index's 6.8% return. Alphabet was the top contributor, driven by accelerating search revenue growth, YouTube stabilization, cloud profitability, and significant AI developments including Bard upgrades and new consumer tools. The managers view AI as transformational, comparable to the desktop-to-mobile transition. Alibaba was the top detractor amid Chinese economic headwinds and competitive pressures, though the managers maintain conviction based on attractive 5x EBITA valuation, strong free cash flow generation, and management's restructuring efforts to unlock value. New positions were initiated in ConocoPhillips and Danaher. ConocoPhillips offers high-quality drilling inventory and is expected to return over 100% of market cap to shareholders over ten years while growing production. Danaher provides exposure to secular growth in biologics and genomics, with near-term pandemic headwinds creating an attractive entry point. The portfolio ended with 56.5% US exposure, 33.2% UK/Europe, and 10.3% Asia, reflecting the fund's global value approach.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

The managers demonstrate high conviction through concentrated positioning with named holdings and specific allocation percentages (Alphabet 8.8%, others 2.9-3.0%). They provide detailed fundamental analysis, specific catalysts with timeframes, and express willingness to hold through volatility. The 10-year outlook for ConocoPhillips and detailed thesis work on each position reflects strong conviction in their research process.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The managers express cautious optimism with mixed signals. They acknowledge challenging conditions in China and advertising headwinds but highlight positive developments in AI and specific company fundamentals. The tone is constructive but measured, recognizing both opportunities and risks in the current environment.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

The fund added two new positions (ConocoPhillips and Danaher) while selling one (HCA Healthcare), indicating selective risk-taking. The managers maintain conviction in existing holdings despite headwinds, suggesting moderate risk appetite with disciplined position management based on valuation targets.

Capital Deployment

15%

De-riskingDeploying

De-risking (15%)

The fund added two new positions while selling one, representing modest net deployment activity. Without specific cash level changes disclosed, the activity suggests selective rotation rather than aggressive capital deployment. The measured approach to adding positions indicates cautious but positive deployment bias.

Forward Guidance

35%

CautiousExpansionary

Cautious (35%)

The managers express confidence in specific catalysts including Alphabet's AI developments and cost initiatives bearing fruit in 2024, Alibaba's restructuring efforts, and ConocoPhillips' long-term shareholder return potential. However, they acknowledge near-term headwinds and maintain a measured approach to deployment.

Language Signal

30%

BearishBullish

Bearish (30%)

Language is balanced with positive terms like 'attractive,' 'impressive,' 'excellent track record,' and 'competitive differentiator' offset by risk language including 'headwinds,' 'struggling,' 'degraded sentiment,' and 'pressured.' The net balance leans slightly positive but remains measured throughout.

Perceived Risk

55%

Low RiskElevated

Moderate Risk (55%)

The managers identify several specific risks including China's economic struggles, U.S.-China political tensions, advertising spending declines, and pandemic-related headwinds for Danaher. These risks are discussed with meaningful detail and context, indicating moderate risk awareness without alarm.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

The managers found attractive opportunities to add two new positions while maintaining conviction in existing holdings. They describe specific value opportunities in energy (ConocoPhillips underperformance) and life sciences (Danaher's discounted valuation), suggesting a reasonably rich opportunity set for selective investors.

Time Horizon

75%

Short-TermLong-Term

Decade+ (75%)

The managers demonstrate a long-term orientation with explicit 10-year projections for ConocoPhillips shareholder returns and multi-year outlook for AI development at Alphabet. They express willingness to hold through near-term volatility and focus on secular growth themes, indicating a patient capital approach with multi-year investment horizons.